ICON Public Limited Company - Asset Resilience Ratio
ICON Public Limited Company (IJF) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ICON Public Limited Company strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how ICON Public Limited Company's Asset Resilience Ratio has changed over time. See IJF equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ICON Public Limited Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ICON Public Limited Company (IJF) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ICON Public Limited Company maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
ICON Public Limited Company Industry Peers by Asset Resilience Ratio
Compare ICON Public Limited Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for ICON Public Limited Company (2016–2024)
The table below shows the annual Asset Resilience Ratio data for ICON Public Limited Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€16.88 Billion ≈ $19.73 Billion |
-- |
| 2023-12-31 | 0.01% | €1.95 Million ≈ $2.28 Million |
€16.99 Billion ≈ $19.86 Billion |
+0.00pp |
| 2022-12-31 | 0.01% | €1.71 Million ≈ $2.00 Million |
€17.26 Billion ≈ $20.17 Billion |
+0.00pp |
| 2021-12-31 | 0.01% | €1.71 Million ≈ $2.00 Million |
€17.39 Billion ≈ $20.33 Billion |
-0.04pp |
| 2020-12-31 | 0.05% | €1.73 Million ≈ $2.02 Million |
€3.44 Billion ≈ $4.02 Billion |
-1.66pp |
| 2019-12-31 | 1.71% | €49.63 Million ≈ $58.02 Million |
€2.91 Billion ≈ $3.40 Billion |
-0.84pp |
| 2018-12-31 | 2.54% | €59.91 Million ≈ $70.04 Million |
€2.35 Billion ≈ $2.75 Billion |
-1.07pp |
| 2017-12-31 | 3.61% | €77.59 Million ≈ $90.71 Million |
€2.15 Billion ≈ $2.51 Billion |
-0.11pp |
| 2016-12-31 | 3.73% | €68.05 Million ≈ $79.55 Million |
€1.83 Billion ≈ $2.13 Billion |
-- |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more